Spyre报告了早期TL1A抗体试验的结果

2025-06-17 21:46

Spyre Therapeutics (NASDAQ:SYRE) reported updates from its initial early stage studies involving SPY002 and SPY072, the company's new monoclonal antibodies designed to target TL1A.
In the studies, SPY002 and SPY072 were found to be safe for patients and showed that they can be given every three months or less.
The most frequently reported side effects for SPY002 and SPY072 included COVID-19 and nausea, affecting more than two study participants.
The treatments interacted with TL1A throughout a follow-up period lasting up to 20 weeks, demonstrating a half-life of approximately 75 days, which is over three times longer than older anti-TL1A antibodies.
The company also announced the start of two other clinical studies aimed at treating ulcerative colitis and several types of arthritis.

More on Spyre Therapeutics